Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Vitreal penetration of oral moxifloxacin in humans.

Lott MN, Fuller JJ, Hancock HA, Singh J, Singh H, McGwin G Jr, Marcus DM.

Retina. 2008 Mar;28(3):473-6. doi: 10.1097/IAE.0b013e31814fb0ed.

PMID:
18327141
2.

Vitreal penetration of oral and topical moxifloxacin in humans.

Fuller JJ, Lott MN, Henson NM, Bhatti AA, Singh H, McGwin G Jr, Marcus DM.

Am J Ophthalmol. 2007 Feb;143(2):338-40. Epub 2006 Oct 23.

PMID:
17258525
3.

Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy.

Lai WW, Chu KO, Chan KP, Choy KW, Wang CC, Tsang CW, Pang CP.

Am J Ophthalmol. 2007 Aug;144(2):315-8.

PMID:
17659971
4.

Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.

Hariprasad SM, Mieler WE, Shah GK, Blinder KJ, Apte RS, Holekamp NM, Thomas MA, Chi J, Prince RA.

Trans Am Ophthalmol Soc. 2004;102:149-55; discussion 155-7.

5.

Vitreous and aqueous penetration of orally administered moxifloxacin in humans.

Vedantham V, Lalitha P, Velpandian T, Ghose S, Mahalakshmi R, Ramasamy K.

Eye (Lond). 2006 Nov;20(11):1273-8. Epub 2006 Sep 30.

PMID:
16200061
6.

Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose.

Wacke R, Förster S, Adam U, Mundkowski RG, Klar E, Hopt UT, Drewelow B.

J Antimicrob Chemother. 2006 Nov;58(5):994-9. Epub 2006 Sep 6.

PMID:
16956903
7.

Vitreous penetration of topical moxifloxacin and gatifloxacin in humans.

Costello P, Bakri SJ, Beer PM, Singh RJ, Falk NS, Peters GB, Melendez JA.

Retina. 2006 Feb;26(2):191-5.

PMID:
16467677
8.

Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration.

Fiscella RG, Lai WW, Buerk B, Khan M, Rodvold KA, Pulido JS, Labib S, Shapiro MJ, Blair NP.

Ophthalmology. 2004 Jun;111(6):1191-5.

PMID:
15177970
9.

Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin.

Vasavada AR, Gajjar D, Raj SM, Vasavada V, Vasavada V.

J Cataract Refract Surg. 2008 Aug;34(8):1379-82. doi: 10.1016/j.jcrs.2008.04.027.

PMID:
18655991
10.

Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.

Hariprasad SM, Shah GK, Chi J, Prince RA.

J Cataract Refract Surg. 2005 Nov;31(11):2142-6.

PMID:
16412929
11.

The effect of cataract surgery on ocular levels of topical moxifloxacin.

Mather R, Stewart JM, Prabriputaloong T, Wong J, McLeod SD.

Am J Ophthalmol. 2004 Oct;138(4):554-9.

PMID:
15488780
12.

Intravitreal clearance of moxifloxacin.

Iyer MN, He F, Wensel TG, Mieler WF, Benz MS, Holz ER.

Trans Am Ophthalmol Soc. 2005;103:76-81; discussion 81-3.

13.

Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor.

Katz HR, Masket S, Lane SS, Sall K, Orr SC, Faulkner RD, McCue BA, Dahlin DC.

Cornea. 2005 Nov;24(8):955-8.

PMID:
16227840
14.

Penetration of ofloxacin in human aqueous and vitreous humors following oral and topical administration.

Cekic O, Batman C, Yasar U, Basci NE, Bozkurt A, Kayaalp SO.

Retina. 1998;18(6):521-5.

PMID:
9869460
15.

Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin.

García-Sáenz MC, Arias-Puente A, Fresnadillo-Martinez MJ, Carrasco-Font C.

J Cataract Refract Surg. 2001 Dec;27(12):1969-74.

PMID:
11738912
16.

Vitreous and aqueous penetration of orally and topically administered moxifloxacin.

Fukuda M, Shibata N, Osada H, Yamashiro Y, Sasaki H.

Ophthalmic Res. 2011;46(3):113-7. doi: 10.1159/000319752. Epub 2011 Feb 12.

PMID:
21325873
17.

Bacterial contamination of the vitreous cavity associated with transconjunctival 25-gauge microincision vitrectomy surgery.

Tominaga A, Oshima Y, Wakabayashi T, Sakaguchi H, Hori Y, Maeda N.

Ophthalmology. 2010 Apr;117(4):811-7.e1. doi: 10.1016/j.ophtha.2009.09.030. Epub 2010 Jan 25.

PMID:
20097429
18.

Aqueous and vitreous penetration of levofloxacin after oral administration.

Fiscella RG, Nguyen TK, Cwik MJ, Phillpotts BA, Friedlander SM, Alter DC, Shapiro MJ, Blair NP, Gieser JP.

Ophthalmology. 1999 Dec;106(12):2286-90.

PMID:
10599658
19.

Effects of intravitreal moxifloxacin and dexamethasone in experimental Staphylococcus aureus endophthalmitis.

Ermis SS, Cetinkaya Z, Kiyici H, Inan UU, Ozturk F.

Curr Eye Res. 2007 Apr;32(4):337-44.

PMID:
17453955
20.

Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.

Hariprasad SM, Blinder KJ, Shah GK, Apte RS, Rosenblatt B, Holekamp NM, Thomas MA, Mieler WF, Chi J, Prince RA.

Arch Ophthalmol. 2005 Jan;123(1):39-44.

PMID:
15642810

Supplemental Content

Support Center